The research Dr. Thomas presented found that Rheumavax was safe. Investigators did not observe any major adverse events. The results that the researchers observed were in patients with anticitrullinated protein antibody–treated early RA.
You Might Also Like
- ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
- Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting
- 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
Explore This IssueApril 2012
Also By This Author
“There’s potential for further development of strategies targeting dendritic cells and cit-peptide in specific HLA-DR groups,” Dr. Thomas said. “The tolerance biomarkers suggest improvement in immune hyperregulation.”
Vanessa Caceres is a freelance medical writer in Bradenton, Fla.